Deferasirox: oral, once daily iron chelator--an expert opinion.
Iron overload is a serious and potentially fatal condition that results from multiple blood transfusions required over a long period of time to treat certain types of anemias such as, that caused by beta-thalassemia, sickle cell disease and myelodysplastic syndrome. Deferoxamine, which has been used since four decades as an iron chelator has limited efficacy due to its demanding therapeutic regimen, leading to poor compliance. Deferasirox, once daily oral iron chelator provides an effective alternative to Deferoxamine in the treatment of transfusional hemosiderosis. In this review, the role of Deferasirox as an ideal iron chelator has been discussed. Pubmed searches on Deferasirox were carried out for the same. Several studies demonstrated the safety and efficacy of Deferasirox in reducing iron burden in iron-overloaded patients with beta-thalassemia, sickle cell anemia and myelodysplastic anemia. Thus, convenient, effective and tolerable chelation therapy with oral Deferasirox is likely to be a significant development in the treatment of transfusional iron overload, due to its ability to provide constant chelation coverage and the potential to improve compliance.
Agarwal
M B
MB
Bombay Hospital Institute of Medical Sciences, Marine Lines, Mumbai, India. mbagarwal@hotmail.com
D001565:Benzoates / Q000737:chemistry / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000453:epidemiology; D002614:Chelating Agents / Q000737:chemistry / Q000627:therapeutic use*; D000077588:Deferasirox; D006486:Hemosiderosis / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D013789:Thalassemia / Q000453:epidemiology / Q000378:metabolism; D014230:Triazoles / Q000737:chemistry / Q000627:therapeutic use*
D001565:Benzoates; D002614:Chelating Agents; D014230:Triazoles; D007501:Iron; D000077588:Deferasirox